Nevro Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Public

  • Employees
  • 1,215

Employees

  • Stock Symbol
  • NVRO

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $9.81
  • (As of Wednesday Closing)

Nevro General Information

Description

Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain. Senza generates electrical impulses to relieve pain. The system is implanted by physicians and controlled by patients. It consists of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. The company generates the majority of its revenue in the United States.

Contact Information

Website
www.nevro.com
Formerly Known As
NBI Development
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Therapeutic Devices
Stock Exchange
NYS
Corporate Office
  • 1800 Bridge Parkway
  • Redwood City, CA 94065
  • United States
+1 (650) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Nevro Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$9.81 $9.96 $8.93 - $28.42 $360M 36.7M 534K -$2.29

Nevro Financials Summary

In Thousands,
USD
TTM 31-Mar-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 418,967 654,085 1,214,319 2,618,193
Revenue 430,746 425,174 406,365 386,905
EBITDA (77,062) (92,476) 17,002 (103,070)
Net Income (82,593) (92,213) 3,001 (131,360)
Total Assets 596,050 635,713 602,408 574,544
Total Debt 217,899 216,105 197,163 166,712
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Nevro Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Nevro‘s full profile, request access.

Request a free trial

Nevro Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Nevro‘s full profile, request access.

Request a free trial

Nevro Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which include
Therapeutic Devices
Redwood City, CA
1,215 As of 2023
00000
000000000 00000

000000

tate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat
00000000000 0000000
Alameda, CA
0000 As of 0000
0000
00000 0000-00-00
00000000 0000

00000-

ute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat
00000000000 0000000
Mineral Wells, TX
00 As of 0000
000000000 -
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Nevro Competitors (19)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Penumbra Formerly VC-backed Alameda, CA 0000 0000 00000000 0000
Alpha-Stim Private Equity-Backed Mineral Wells, TX 00 000000000 -
Mainstay Medical Venture Capital-Backed San Diego, CA 000 00000 0000000000 0 00000
ZetrOZ Venture Capital-Backed Trumbull, CT 00 000.00 0000000000 000.00
Saluda Medical Venture Capital-Backed Artarmon, Australia 000 00000 00000000000 00000
You’re viewing 5 of 19 competitors. Get the full list »

Nevro Patents

Nevro Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240017068-A1 Systems and methods for delivering neurostimulation, including reduced doses of neurostimulation Pending 15-Jul-2022 00000000000
US-20240001121-A1 Neurostimulation for treating sensory deficits, and associated systems and methods Pending 01-Jul-2022 00000000000 0
US-20220401730-A1 Neurostimulation waveforms having a base component and a high frequency component, and associated systems and methods Pending 11-Jun-2021 0000000000 0
AU-2022287979-A1 Neurostimulation waveforms having a base component and a high frequency component, and associated systems and methods Pending 11-Jun-2021 0000000000
EP-4351711-A1 Neurostimulation waveforms having a base component and a high frequency component, and associated systems and methods Pending 11-Jun-2021 A61N1/0551
To view Nevro’s complete patent history, request access »

Nevro Executive Team (31)

Name Title Board Seat Contact Info
Kevin Thornal Chief Executive Officer, President & Board Member
Roderick MacLeod Chief Financial Officer, Finance & Senior Vice President
Christopher Christoforou Chief Operating Officer, Operations
Greg Siller Executive & Senior Vice President
Kashif Rashid JD Executive & Senior Vice President
You’re viewing 5 of 31 executive team members. Get the full list »

Nevro Board Members (23)

Name Representing Role Since
D. Grossman Nevro Chairman & Board Member 000 0000
Elizabeth Weatherman Self Board Member 000 0000
Frank Fischer Self Board Member 000 0000
Karen Prange Self Board Member 000 0000
Kevin O'Boyle Self Board Member 000 0000
You’re viewing 5 of 23 board members. Get the full list »

Nevro Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Nevro Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Nevro‘s full profile, request access.

Request a free trial

Nevro Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Vyrsa Technologies 30-Nov-2023 0000000000 000.00 Surgical Devices 00000 000
To view Nevro’s complete acquisitions history, request access »

Nevro Subsidiaries (1)

Company Name Industry Location Founded
Vyrsa Technologies Surgical Devices King of Prussia, PA 0000
To view Nevro’s complete subsidiaries history, request access »

Nevro ESG

Risk Overview

Risk Rating

Updated September, 16, 2023

21.95 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.00

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 16,421

Rank

00.00

Percentile

Healthcare

Industry

00 of 645

Rank

00.00

Percentile

Medical Devices

Subindustry

00 of 228

Rank

0.00

Percentile

To view Nevro’s complete esg history, request access »

Nevro FAQs

  • When was Nevro founded?

    Nevro was founded in 2006.

  • Who is the CEO of Nevro?

    Kevin Thornal is the CEO of Nevro.

  • Where is Nevro headquartered?

    Nevro is headquartered in Redwood City, CA.

  • What is the size of Nevro?

    Nevro has 1,215 total employees.

  • What industry is Nevro in?

    Nevro’s primary industry is Therapeutic Devices.

  • Is Nevro a private or public company?

    Nevro is a Public company.

  • What is Nevro’s stock symbol?

    The ticker symbol for Nevro is NVRO.

  • What is the current stock price of Nevro?

    As of 22-May-2024 the stock price of Nevro is $9.81.

  • What is the current market cap of Nevro?

    The current market capitalization of Nevro is $360M.

  • What is Nevro’s current revenue?

    The trailing twelve month revenue for Nevro is $431M.

  • Who are Nevro’s competitors?

    Penumbra, Alpha-Stim, Mainstay Medical, ZetrOZ, and Saluda Medical are some of the 19 competitors of Nevro.

  • What is Nevro’s annual earnings per share (EPS)?

    Nevro’s EPS for 12 months was -$2.29.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »